Search results for: 'Software-as-a-Service china'

ViVE 2026, held February 22–25 in Los Angeles, brought together more than 7,000 attendees, 230+ speakers, and 300 exhibitors to define the year’s direction in digital health. It reinforced a pivotal message for the healthcare IT ecosystem: AI has moved beyond experimentation and is now a core enterprise capability requiring scale, governance, and a...

The SCOPE Summit 2026, held in Orlando, Florida, from February 2 to 5, 2026, highlighted the dominance of small- to mid-segment companies and specialized CROs focusing on specific therapy areas or aspects of clinical trials, such as bioanalysis. With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) highlights recent advances in biological therapies such as RNA therapies, biosimilars, gene therapies and cell therapies for the management of diseases such as cancer, neurodegenerative disorders and rare diseases. The research also provides technological insigh...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping diagnostics, therapeutics, and clinical workflows across infectious diseases, women’s health, metabolic disorders, neurodegeneration, oncology, rare diseases, and musculoskeletal care. It hi...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in oncology, immunology, autoimmune disorders, and precision medicine, highlighting next-generation biologics, bispecific antibodies, kinase inhibitors, molecular glues, and antibody engineering platforms. The...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming precision therapeutics, regenerative medicine, AI-enabled discovery, laboratory automation, targeted delivery, vaccines, and biomanufacturing across oncology, chronic disease, neurologica...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) encompasses insights across advances in targeted neurological therapies, cancer treatments, and AI-powered drug development. The TOE also features innovators for treatment of metabolic diseases such as obesity and heart failure.The Life Science, Health & Wellnes...

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...